Document is current
Any future updates will be listed below
-
Authors
Innes, Andrew J. https://orcid.org/0000-0003-0918-8882
Hayden, Chloe
Orovboni, Victoria
Claudiani, Simone
Fernando, Fiona
Khan, Afzal
Rees, David
Byrne, Jennifer
Gallipoli, Paolo https://orcid.org/0000-0001-7254-2253
Francis, Sebastian
Copland, Mhairi https://orcid.org/0000-0002-7655-016X
Horne, Gillian https://orcid.org/0000-0001-9741-7352
Raghavan, Manoj https://orcid.org/0000-0002-5464-2602
Arnold, Claire
Collins, Angela
Cranfield, Tanya
Cunningham, Nicholas
Danga, Akila
Forsyth, Peter
Frewin, Rebecca
Garland, Paula
Hannah, Guy
Avenoso, Daniele https://orcid.org/0000-0003-4218-4170
Hassan, Sandra
Huntly, Brian J. P. https://orcid.org/0000-0003-0312-161X
Husain, Jissan
Makkuni, Sudhakaran
Rothwell, Kate
Khorashad, Jamshid
Apperley, Jane F.
Milojkovic, Dragana
- License Information
-
More Information
Article History
Received: 24 April 2024
Revised: 28 August 2024
Accepted: 5 September 2024
First Online: 17 September 2024
Competing interests
: AJI: Speakers bureau (Incyte), speakers bureau and advisory board (Novartis). JB: Speaker fees and advisory board (Novartis and Incyte). MC: Research funding (Cyclacel and Incyte), advisory board member (Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier), honoraria (Astellas, Novartis). RF: Honoraria (Novartis, BMS), advisory board (CTI biopharma and GSK). GHa: Honoraria and Speakers fees (Novartis, Pfizer, Incyte), Advisory board (Novartis), DA: Speaker fees (Incyte). JFA: Honoraria, research funding, and speakers bureau (Incyte, Pfizer); honoraria and speakers bureau (Bristol Myers Squibb, Novartis). DM: Honoraria (Incyte, Novartis, Pfizer, Ascentage Pharma), Research funding (Incyte and Pfizer). The remaining authors (CH VO, SC FF AK, DR, PG, SF, GHo, MR, CA, AC, TC, NC, AD, PF, PG, SH, BJPH, JH, SM, KR, JK) report no conflict of interest.
: This work in this study was performed in line with current guidance (with UKAS accredited assays), and the study was approved by a local research ethics committee (HRA and Health and Care Research Wales, reference 21/HRA/2157).
